RetinalGenix Technologies Inc., a developmental-stage company specializing in ophthalmic screening and pharmacogenetic mapping, has entered into an agreement with LabCorp to support its DNA/RNA/GPS Pharmaco-Genetic Mapping platform. This collaboration aims to make genetic testing and high-resolution retinal imaging more accessible and cost-effective, reducing the need for expensive diagnostics like MRI and CT scans. The initiative is designed to allow early detection of eye and systemic diseases, enhancing diagnostic accuracy and broadening access to screening services. Patients will manage their appointments and test orders online, with results securely released after payment validation at LabCorp centers.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。